Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Arnhem – page 61

787 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Arnhem at a glance
787
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

787 trials in Arnhem

Open in trial search

Acute myocardial infarction+5

Not recruiting

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zalunfiban
  • Sponsor:Celecor Therapeutics Inc.

Bladder cancer+2

Not recruiting

Study on Pre-Operative Nivolumab and Relatlimab for Adults with Stage II-IIIa Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Transitional cell carcinoma

Not recruiting

Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Thyroid cancer metastatic

Not recruiting

Study on Digoxin and Sodium Iodide (123 I) for Patients with Advanced Non-Medullary Thyroid Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Digoxin
  • Sponsor:Radboud universitair medisch centrum Stichting

IgA nephropathy

Not recruiting

Study on Sibeprenlimab for Patients with IgA Nephropathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development And Commercialization Inc.

Gastrointestinal stromal tumour

Not recruiting

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Cogent Biosciences Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage I+1

Not recruiting

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Infertility+2

Not recruiting

Study on Progesterone for Improving Birth Rates in Couples with Unexplained Infertility Undergoing Mild Ovarian Stimulation and Intrauterine Insemination

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Universitair Medisch Centrum Utrecht

Partial lipodystrophy

Not recruiting

Study on Metreleptin for Patients with Partial Lipodystrophy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metreleptin
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

  • Gastric Cancer Staging
  • Bladder Cancer Therapeutics
  • Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

  • Stroke Treatment Protocols
  • Cardiac Arrest Management
  • Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

  • Weight Management Therapies
  • Metabolic Disease Treatment
  • Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.